EDWARDS LIFESCIENCES ($EW) posted quarterly earnings results on Thursday, October 30th. The company reported earnings of $0.67 per share, beating estimates of $0.61 by $0.06. The company also reported revenue of $1,553,100,000, beating estimates of $1,539,517,485 by $13,582,515.
You can see Quiver Quantitative's $EW stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
EDWARDS LIFESCIENCES Insider Trading Activity
EDWARDS LIFESCIENCES insiders have traded $EW stock on the open market 12 times in the past 6 months. Of those trades, 0 have been purchases and 12 have been sales.
Here’s a breakdown of recent trading of $EW stock by insiders over the last 6 months:
- BERNARD J ZOVIGHIAN (CEO) has made 0 purchases and 3 sales selling 23,046 shares for an estimated $1,765,813.
- LARRY L WOOD (Global President TAVR & Surg) has made 0 purchases and 2 sales selling 17,900 shares for an estimated $1,371,947.
- SCOTT B. ULLEM (CVP, Chief Financial Officer) sold 11,250 shares for an estimated $837,034
- DANIEL J. LIPPIS (CVP, JAPAC) has made 0 purchases and 2 sales selling 4,444 shares for an estimated $351,460.
- DAVEEN CHOPRA (CVP, TMTT) has made 0 purchases and 2 sales selling 4,000 shares for an estimated $317,477.
- DONALD E JR BOBO (CVP,Strategy/Corp Development) sold 2,570 shares for an estimated $198,911
- WAYNE MARKOWITZ (GM & SVP, Surgical) sold 268 shares for an estimated $20,120
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
EDWARDS LIFESCIENCES Hedge Fund Activity
We have seen 557 institutional investors add shares of EDWARDS LIFESCIENCES stock to their portfolio, and 572 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FISHER ASSET MANAGEMENT, LLC removed 9,784,074 shares (-96.9%) from their portfolio in Q2 2025, for an estimated $765,212,427
- WELLINGTON MANAGEMENT GROUP LLP removed 9,308,307 shares (-31.9%) from their portfolio in Q2 2025, for an estimated $728,002,690
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 5,307,192 shares (-78.2%) from their portfolio in Q2 2025, for an estimated $415,075,486
- JPMORGAN CHASE & CO added 4,811,521 shares (+21.9%) to their portfolio in Q2 2025, for an estimated $376,309,057
- DZ BANK AG DEUTSCHE ZENTRAL GENOSSENSCHAFTS BANK, FRANKFURT AM MAIN added 4,805,819 shares (+111.2%) to their portfolio in Q2 2025, for an estimated $375,863,103
- MARSHALL WACE, LLP added 3,864,908 shares (+127.5%) to their portfolio in Q2 2025, for an estimated $302,274,454
- MILLENNIUM MANAGEMENT LLC added 3,237,236 shares (+94.0%) to their portfolio in Q2 2025, for an estimated $253,184,227
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
EDWARDS LIFESCIENCES Government Contracts
We have seen $25,422,762 of award payments to $EW over the last year.
Here are some of the awards which we have have seen pay out the most over the last year:
- EXPRESS REPORT: HEART VALVES: $295,500
- EXPRESS REPORT: 2ND QTR FY25 TAVR HEART VALVES WITH CONSIGNMENT DELIVERY: $261,500
- HTM EV1000 PATIENT MONITORS: $246,000
- HEART VALVE: $238,000
- EDWARDS LIFESCIENCES HEART VALVES: $204,000
To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard.
EDWARDS LIFESCIENCES Congressional Stock Trading
Members of Congress have traded $EW stock 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $EW stock by members of Congress over the last 6 months:
- REPRESENTATIVE JEFFERSON SHREVE sold up to $100,000 on 05/12.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
EDWARDS LIFESCIENCES Analyst Ratings
Wall Street analysts have issued reports on $EW in the last several months. We have seen 9 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Jefferies issued a "Buy" rating on 10/29/2025
- Stifel issued a "Buy" rating on 09/22/2025
- Wells Fargo issued a "Overweight" rating on 08/07/2025
- Barclays issued a "Overweight" rating on 07/25/2025
- Mizuho issued a "Outperform" rating on 07/25/2025
- RBC Capital issued a "Outperform" rating on 07/25/2025
- Piper Sandler issued a "Overweight" rating on 07/25/2025
To track analyst ratings and price targets for EDWARDS LIFESCIENCES, check out Quiver Quantitative's $EW forecast page.
EDWARDS LIFESCIENCES Price Targets
Multiple analysts have issued price targets for $EW recently. We have seen 15 analysts offer price targets for $EW in the last 6 months, with a median target of $88.0.
Here are some recent targets:
- Matthew Taylor from Jefferies set a target price of $98.0 on 10/29/2025
- Richard Newitter from Truist Securities set a target price of $87.0 on 10/28/2025
- Vijay Kumar from Evercore ISI Group set a target price of $88.0 on 10/07/2025
- Rick Wise from Stifel set a target price of $85.0 on 09/22/2025
- Larry Biegelsen from Wells Fargo set a target price of $88.0 on 08/07/2025
- Matt Miksic from Barclays set a target price of $95.0 on 07/25/2025
- Shagun Singh from RBC Capital set a target price of $89.0 on 07/25/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
